Floatz logo

Immunoglobulin G1 [De-449-Lysine], Anti-(Human Tau Protein) (Human-Mus Musculus Monoclonal E2814 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal E2814 .Kappa.-Chain, Dimer

Dementia

Explore 43 assets in Dementia →
Floatz Rating
CCC55/100
Confidence
Indicative
v0.2
Sponsor
Washington University School of Medicine
Modality
monoclonal_antibody
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05269394CT.gov
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
—Active Not Recruiting———
NCT01760005CT.gov
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
—Active Not Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Dementia

AssetSponsorPhaseRating
Immunoglobulin G1 [De-449-Lysine], Anti-(Human Tau Protein) (Human-Mus Musculus Monoclonal E2814 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal E2814 .Kappa.-Chain, Dimer (this asset)Washington University School of MedicineP2/3CCC · 55
RisperidoneHannover Medical SchoolP4BBB
CitalopramHannover Medical SchoolP4BBB
MemantineZealand University HospitalP4BB
EscitalopramOhio State UniversityP4BB
Galantamine HydrobromideJanssen Pharmaceutica N.V., BelgiumP3BB
IoflupaneMayo ClinicP4BB
OlanzapineHannover Medical SchoolP4BB
SertralineHannover Medical SchoolP4BB

+42 more in the Dementia cohort

Other indications for Immunoglobulin G1 [De-449-Lysine], Anti-(Human Tau Protein) (Human-Mus Musculus Monoclonal E2814 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal E2814 .Kappa.-Chain, Dimer

IndicationSponsorPhaseRating
Alzheimer Disease—P2/3BB · 66
Familial Alzheimer Disease—P2/3B · 57

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Immunoglobulin G1 [De-449-Lysine], Anti-(Human Tau Protein) (Human-Mus Musculus Monoclonal E2814 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal E2814 .Kappa.-Chain, Dimer in Dementia. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g1-de-449-lysine-anti-human-tau-protein-human-mus-musculus-monoclonal-e2814-1-chain-disulfide-with-human-mus-musculus-monoclonal-e2814-kappa-chain-dimer-dementia

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →